LOGIN  |  REGISTER
Amneal Pharmaceuticals

List of Biotech and Pharma Companies Using Artificial Intelligence

Company
Last Trade
Change
Volume
Shares Out
Market Cap
US$ 1.00
5.12 0.50
4.04M
895.02M
US$ 915.520B
US$ 195.25
0.86 0.44
8.15M
2.41B
US$ 470.550B
US$ 580.12
-7.90 -1.34
2.50M
375.71M
US$ 217.960B
US$ 565.51
-6.94 -1.21
1.52M
354.50M
US$ 200.470B
US$ 79.24
-1.02 -1.27
6.86M
1.27B
US$ 100.630B
US$ 270.89
0.28 0.10
2.62M
267.13M
US$ 72.360B
US$ 193.04
0.92 0.48
3.60M
286.63M
US$ 55.330B
US$ 291.70
-5.26 -1.77
805,990
163.91M
US$ 47.810B
US$ 223.55
2.67 1.21
2.34M
170.30M
US$ 38.070B
US$ 73.97
-1.01 -1.35
1.46M
455.52M
US$ 33.690B
US$ 59.68
0.07 0.12
4.16M
390.02M
US$ 23.280B
US$ 267.87
1.87 0.70
1.23M
82.90M
US$ 22.210B
US$ 187.58
0.73 0.39
1.36M
111.24M
US$ 20.870B
US$ 105.41
-2.85 -2.63
1.27M
196.32M
US$ 20.690B
US$ 119.93
-2.05 -1.68
1.42M
152.80M
US$ 18.330B
US$ 74.26
-0.30 -0.40
2.96M
222.57M
US$ 16.530B
US$ 163.45
0.03 0.02
358,579
76.36M
US$ 12.480B
US$ 94.13
-3.71 -3.79
1.89M
126.04M
US$ 11.860B
US$ 68.16
-2.94 -4.14
6.36M
172.86M
US$ 11.780B
US$ 93.40
-0.73 -0.78
1.12M
113.38M
US$ 10.590B
US$ 44.65
0.12 0.27
852,432
216.84M
US$ 9.680B
US$ 60.75
-0.65 -1.06
2.03M
155.81M
US$ 9.470B
US$ 99.50
-1.00 -1.00
507,910
86.16M
US$ 8.570B
US$ 169.21
-2.29 -1.34
1.12M
49.22M
US$ 8.330B
US$ 24.30
-0.47 -1.90
1.29M
282.15M
US$ 6.860B
US$ 35.75
-1.15 -3.12
2.15M
191.32M
US$ 6.840B
US$ 73.46
-0.99 -1.33
778,694
77.10M
US$ 5.660B
US$ 168.50
-10.62 -5.93
373,939
32.22M
US$ 5.430B
US$ 130.35
-6.09 -4.46
553,755
28.90M
US$ 3.770B
US$ 13.94
-1.16 -7.68
17.06M
252.28M
US$ 3.520B
US$ 72.53
-2.28 -3.05
281,274
42.45M
US$ 3.080B
US$ 31.82
-0.13 -0.41
675,686
87.67M
US$ 2.790B
US$ 16.35
-0.34 -2.04
2.28M
116.47M
US$ 1.900B
US$ 17.28
-0.21 -1.20
3.40M
105.73M
US$ 1.830B
US$ 29.90
-1.97 -6.18
1.19M
60.36M
US$ 1.800B
US$ 22.53
-0.62 -2.68
416,790
59.91M
US$ 1.350B
US$ 8.41
0.13 1.57
1.95M
159.27M
US$ 1.340B
US$ 7.07
-0.40 -5.35
6.50M
177.47M
US$ 1.250B
US$ 2.47
-0.04 -1.59
6.21M
421.82M
US$ 1.040B
C$ 4.11
-0.05 -1.20
1.79M
253.88M
C$ 1.040B
US$ 8.26
-0.40 -4.62
1.54M
80.45M
US$ 664.520M
US$ 6.35
-0.19 -2.91
1.05M
93.21M
US$ 591.880M
US$ 3.23
-0.16 -4.72
1.76M
165.66M
US$ 535.080M
US$ 29.20
0.00 0.00
0
16.17M
US$ 472.160M
US$ 2.07
-0.19 -8.41
8.58M
226.18M
US$ 468.190M
US$ 12.49
-0.36 -2.80
307,798
35.82M
US$ 447.390M
US$ 4.04
-0.20 -4.61
2.19M
104.34M
US$ 421.010M
US$ 2.62
-0.78 -22.94
32.09M
149.52M
US$ 391.740M
US$ 8.00
-0.36 -4.31
1.47M
47.09M
US$ 376.720M
US$ 17.22
-0.11 -0.63
268,674
20.13M
US$ 346.640M
C$ 1.19
-0.03 -2.46
525,432
265.74M
C$ 316.230M
US$ 4.38
0.06 1.39
38,978
67.85M
US$ 297.180M
US$ 3.08
-0.35 -10.20
8.39M
93.50M
US$ 287.980M
US$ 6.00
0.00 0.00
0
40.63M
US$ 243.780M
US$ 2.35
-0.11 -4.47
1.59M
70.37M
US$ 165.370M
US$ 4.42
0.03 0.68
434,491
32.92M
US$ 145.510M
US$ 3.18
-0.02 -0.62
435,759
42.32M
US$ 134.580M
C$ 1.25
0.03 2.46
25,400
85.85M
C$ 107.310M
US$ 3.87
0.00 0.00
0
27.47M
US$ 106.310M
US$ 1.93
0.00 0.00
0
46.15M
US$ 89.070M
US$ 1.05
-0.05 -4.55
1.10M
79.41M
US$ 83.380M
US$ 2.49
-0.13 -4.96
2.01M
29.75M
US$ 74.080M
US$ 2.15
0.00 0.00
22,319
31.11M
US$ 66.890M
US$ 1.57
-0.10 -5.99
149,235
34.31M
US$ 53.870M
US$ 1.65
0.05 3.12
2.37M
30.69M
US$ 50.640M
US$ 5.71
-0.33 -5.46
128,651
8.30M
US$ 47.390M
US$ 3.23
-0.11 -3.29
27,526
13.97M
US$ 45.120M
US$ 3.46
-0.02 -0.57
61,814
10.80M
US$ 37.370M
US$ 0.09
-0.01 -10.53
115,605
434.93M
US$ 36.970M
C$ 0.34
0.02 4.69
29,000
105.09M
C$ 35.210M
US$ 1.35
-0.10 -6.90
1.44M
25.91M
US$ 34.980M
US$ 1.42
0.00 0.00
0
23.18M
US$ 32.920M
US$ 0.35
-0.01 -3.83
453,460
91.96M
US$ 32.370M
US$ 0.95
-0.03 -3.06
165,393
30.81M
US$ 29.270M
C$ 0.36
-0.04 -10.00
63,998
66.61M
C$ 23.980M
US$ 6.50
-0.24 -3.56
48,507
3.50M
US$ 22.750M
US$ 0.73
-0.0031 -0.42
172,316
31.01M
US$ 22.540M
US$ 0.37
-0.02 -6.11
5.11M
60.14M
US$ 22.370M
C$ 0.18
-0.06 -25.00
1.07M
118.78M
C$ 21.380M
US$ 2.07
-0.09 -4.17
14,524
8.76M
US$ 18.130M
C$ 0.10
-0.005 -5.00
7,500
166.73M
C$ 15.840M
US$ 1.18
-0.10 -7.81
242,719
13.26M
US$ 15.650M
C$ 0.09
0.00 0.00
12,003
181.05M
C$ 15.390M
US$ 2.04
0.00 0.00
0
7.09M
US$ 14.440M
C$ 0.12
0.01 9.09
240,000
108.62M
C$ 13.030M
US$ 4.79
-0.66 -12.11
143,321
2.62M
US$ 12.550M
US$ 2.58
-0.28 -9.79
61,061
4.77M
US$ 12.310M
US$ 1.00
-0.09 -8.26
66,283
10.40M
US$ 10.400M
US$ 1.33
-0.17 -11.33
192,988
7.76M
US$ 10.320M
US$ 2.33
-0.01 -0.43
46,666
3.80M
US$ 8.850M
US$ 10.25
7.14 229.58
147,283
834,908
US$ 8.560M
US$ 0.52
-0.02 -2.91
323,756
15.70M
US$ 8.180M
US$ 2.50
-0.02 -0.79
15,135
2.95M
US$ 7.380M
US$ 3.40
-0.34 -9.09
30,532
1.76M
US$ 5.980M
US$ 2.39
0.00 0.00
0
2.39M
US$ 5.710M
C$ 0.03
0.00 0.00
0
176.89M
C$ 5.310M
US$ 1.14
-0.02 -1.72
31,364
4.13M
US$ 4.710M
US$ 4.40
-0.04 -0.90
30,557
959,988
US$ 4.220M
C$ 0.16
0.005 3.23
44,000
21.15M
C$ 3.380M

Latest News From Biotech and Pharma Companies Using Artificial Intelligence


Ascertain and The Oncology Institute Co-Develop ‘Touchless’ AI Automation for Oncology Administration

Partnership deployed touchless prior authorization system in eight weeks, achieving 95% reduction in authorization workload CERRITOS, Calif. and NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Ascertain, a healthcare technology company pioneering agentic AI to automate administrative workflows, and The Oncology Institute, Inc. (NASDAQ: TOI), a leading value-based oncology care provider, today announced a co-development partnership to create “near-touchless” administrative... Read more


HealthEquity to Enhance Member Experience with Agentic AI

Nation's Largest HSA Custodian Leverages Parloa’s Advanced AI Technology to Deliver Personalized, Conversational Support for Millions of Members DRAPER, Utah, Nov. 13, 2025 (GLOBE NEWSWIRE) -- HealthEquity, Inc. (Nasdaq: HQY), the nation's largest Health Savings Account (HSA) and consumer-directed benefits administrator, today announced a new development in building upon its technology investments to transform member experience. The company will deploy agentic AI... Read more


GE HealthCare and RadNet’s DeepHealth Division Sign Letter of Intent to Advance Innovation and Adoption of AI-Powered Imaging Across Multiple Modalities and Remote Scanning

Collaboration aims to expand existing U.S. relationship combining GE HealthCare’s mammography systems with DeepHealth’s Breast Suite to include a worldwide distribution arrangement Intends to integrate GE HealthCare’s ultrasound imaging with DeepHealth’s AI-powered Thyroid Suite for intelligent clinical decision support and advanced automation Creates a proposed offering combining DeepHealth’s remote scanning solution, TechLive™, with GE HealthCare’s... Read more


PainReform’s DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

TEL AVIV, Israel, Nov. 12, 2025 (GLOBE NEWSWIRE) -- PainReform Ltd. (Nasdaq: PRFX) today announced that DeepSolar, its solar energy business unit developing next-generation AI analytics, has advanced the development of its proprietary automated reporting engine, designed to transform how solar-asset performance is analyzed, understood, and communicated. The automated reporting engine reduces manual effort and produces tailored reports according to the customers’ need... Read more


SOPHiA GENETICS and Complete Genomics Integrate Sequencing and AI Analytics to Accelerate Adoption of Precision Medicine

BOSTON, Nov. 11, 2025 /PRNewswire/ -- Complete Genomics, a leading innovator in genomic sequencing, today announced a collaboration with SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, to launch and co-market MSK-ACCESS® and MSK-IMPACT® powered with SOPHiA DDM™ on Complete Genomics' DNBSEQ-T1+ sequencing platform. The companies aim to broaden access to precision oncology testing by offering the best-in-class liquid biopsy and solid tumor... Read more


SOPHiA GENETICS and Element Biosciences Unite Sequencing Power and AI Analytics to Accelerate Global Research In Precision Medicine

BOSTON and SAN DIEGO, Nov. 11, 2025 /CNW/ -- SOPHiA GENETICS (NASDAQ: SOPH), a global leader in AI-driven precision medicine, and Element Biosciences, Inc., a biology company transforming the pace and accessibility of scientific discovery, today announced at the Association for Molecular Pathology (AMP) Annual Meeting a partnership that unites sequencing and AI analytics to streamline genomic workflows and accelerate the research supporting precision medicine. This... Read more


Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

New biomarker and immune data presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting Following the recent presentation of unprecedented two-year clinical efficacy data from the phase 2 trial, the new data further adds to EVX-01’s already strong data package COPENHAGEN, Denmark, November 7, 2025 - Evaxion A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, announces... Read more


Altimmune Presents AI-Based Analysis of Liver Fibrosis Reduction from IMPACT Phase 2b Trial of Pemvidutide in MASH in Late-breaking Poster at AASLD The Liver Meeting® 2025

AI-based digital pathology analysis provides high-resolution quantification of hepatic fibrosis and objective measurement of fibrosis improvement Pemvidutide demonstrated significant reductions in liver fibrosis and improvements in non-invasive tests vs. placebo at 24 weeks GAITHERSBURG, Md., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and... Read more




Wellgistics Health Enters into LOI to Acquire Kare Rx Hub

KareRx to add plug & play telemedicine pharmacy-support vertical and key manufacturer relationships to Wellgistics' offering Telemedicine remote dispensing market expected to grow from $6.7 billion in 2025 to $13.57 billion by 2032 according to Fortune Business Insights Tampa, Florida--(Newsfile Corp. - November 4, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution, digital prescription... Read more


Co-Diagnostics to Integrate and Implement Proprietary Artificial Intelligence Technology into Co-Dx™ Primer Ai™ Platform

Company forms new AI business unit, led by Chief Technology & AI Officer Christopher Thurston, to unify and advance Co-Dx's existing and future AI initiatives SALT LAKE CITY, Nov. 3, 2025 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, today announced the formation of a newly organized, artificial intelligence... Read more


IGC Pharma Expands AI-Powered Drug Discovery In-Silico Pipeline

POTOMAC, MARYLAND / ACCESS Newswire / November 3, 2025 / IGC Pharma, Inc. ("IGC Pharma," "IGC," or the "Company") (NYSE American:IGC), a clinical-stage biotechnology company leveraging AI to develop innovative treatments for Alzheimer's disease, today announced an expansion of its AI-powered in-Silico drug discovery platform. The company is now integrating more methodologies, including retrosynthetic analysis, molecular docking, toxicology and genotoxic assessments, and... Read more


Certara Expands Biosimulation Market with AI-Driven QSP Platform

Certara IQ™ integrates AI and biosimulation to accelerate R&D productivity, reduce risk, and deepen understanding of novel and complex therapies RADNOR, Pa., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in model-informed drug development, today announced the launch of Certara IQ, a scalable, AI-powered Quantitative Systems Pharmacology (QSP) solution. QSP has rapidly become a cornerstone of modern drug discovery and development... Read more


Eli Lilly partners with NVIDIA to build the industry's most powerful AI supercomputer, supercharging medicine discovery and delivery for patients

New AI capabilities will help scientists identify, optimize and validate new molecules Additional applications include manufacturing, medical imaging and enterprise AI agents INDIANAPOLIS, Oct. 28, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced it is building the most powerful supercomputer owned and operated by a pharmaceutical company, in collaboration with NVIDIA. The supercomputer will power an "AI factory," a specialized computing... Read more



Wellgistics Health Enters into Smart Contract Services Agreement with DataVault AI to Develop Patented PharmacyChain(TM) Manufacturer-to-Patient Blockchain-Enabled Tracking & Dispensing Platform for P...

Powered by DataVault AI's High-Performance Computing & Information Exchange, Data Monetization for Traditional and Compound Pharmacies is Set to Become a Reality in the $639 Billion Prescription Drug Market, with Beta Testing Expected in First Half of 2026 Tampa, Florida and Philadelphia, Pennsylvania--(Newsfile Corp. - October 27, 2025) - Wellgistics Health, Inc. (NASDAQ: WGRX) ("Wellgistics"), a leader in next-generation pharmaceutical distribution,... Read more


INVO Fertility Partners with Heidi Health to Bring AI-Powered Tools to INVO’s Wisconsin Fertility Institute

MIDDLETON, Wis. and SARASOTA, Fla., Oct. 27, 2025 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on expanding access to advanced treatment through the establishment, acquisition and operation of fertility clinics and related businesses and technologies, today announced a strategic partnership with Heidi Health to integrate its innovative AI-powered scribe platform at INVO’s Wisconsin... Read more


Guardant Health and Zephyr AI Announce Partnership to Unlock Drug Response Predictions and Biomarker Insights

Strategic partnership will link DNA data with rich clinical data to identify novel biomarkers for targeted cancer therapies The two companies will utilize AI and multimodal molecular data to unlock new insights for personalized oncology treatments PALO ALTO, Calif. & MCLEAN, Va. / Oct 27, 2025 / Business Wire / Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing artificial intelligence to accelerate... Read more


Halberd Successfully Demonstrates its Proprietary Breakthrough AI Technology for Behavioral Analysis Platform

Live Technical Demonstration Validates NeuroSense AI Platform Feasibility; Development Moves Forward with Proven Core Technologies JACKSON CENTER, Pa., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Halberd Corporation (OTC: HALB) today announced the successful completion of a technical feasibility demonstration for NeuroSense AI, its proprietary behavioral intelligence platform in development. The live demonstration, conducted Thursday before key stakeholders, validated the platform's... Read more


DataVault AI and Wellgistics Health Announce Plans for PharmacyChain™ to Implement Manufacturer-to-Patient Blockchain-enabled Smart Contracts for the Prescription Drug Industry to Improve Efficiency...

Strategic Alliance Targets Digital Transformation of the $634.32 Billion (1) U.S. Prescription Drug Market Through Blockchain-Enabled Data Monetization and AI-Driven Efficiency Gains BEAVERTON, Ore., Oct. 22, 2025 (GLOBE NEWSWIRE) -- via IBN -- DataVault AI, Inc. (“DataVault”) (NASDAQ: DVLT), leading the way in AI data experience, valuation, and monetization, and Wellgistics Health, Inc. ("Wellgistics") (NASDAQ: WGRX), a leader in next-generation pharmaceutical... Read more


Hinge Health unveils new AI-powered care tools

SAN FRANCISCO / Oct 21, 2025 / Business Wire / Hinge Health, Inc. (NYSE:HNGE) today announced two AI-powered care tools: Movement Analysis uses computer vision to set a new standard for tracking musculoskeletal (MSK) outcomes, and Robin is an AI Care Assistant that provides instant support for members. Hinge Health also published its AI care principles, which guide the development of AI across its platform. “Our thoughtful investments in AI are transforming how our members... Read more


HEALWELL's DARWEN(TM) AI Platform Demonstrates One of the World's First Examples of Using AI to Generate Regulatory-Grade Real-World Data (RWD) for Supporting Patient Access and Advancing the Pharmaceutical...

HEALWELL, in collaboration with Takeda Pharmaceutical, presented new AI generated and regulatory-grade real-world data (RWD) on vedolizumab dose escalation in ulcerative colitis and Crohn's disease at the prestigious United European Gastroenterology (UEG) Week in Berlin on October 6, 2025. HEALWELL's DARWEN™ AI platform generated real-world data (RWD) demonstrating that vedolizumab dose escalation from every 8 weeks to every 4 weeks improved remission outcomes, supporting... Read more


GE HealthCare collaborates with two major medical systems to advance AI technology designed to transform hospital operations and improve patient care

Queen’s and a nationally recognized academic medical center to provide clinical expertise to enhance GE HealthCare’s forthcoming software solution New software solution will use AI and predictive analytics to recommend actions and help care teams improve quality of care, patient flow, and maximize resources CHICAGO / Oct 20, 2025 / Business Wire / GE HealthCare (Nasdaq: GEHC) today announced collaborations with two leading U.S. health systems—The Queen’s Health... Read more


Becton Dickinson Launches New AI-enabled Solutions to Drive Connectivity Across Healthcare Settings

FRANKLIN LAKES, N.J., Oct. 20, 2025 /PRNewswire/ -- BD (Becton, Dickinson and Company) (NYSE: BDX), a global leader in medical technology, introduces the BD Incada™ Connected Care Platform, a new scalable, AI-enabled, cloud-based platform that unifies BD device data into one intelligent ecosystem for the first time. The BD Incada™ Platform is available now with the launch of the next-generation BD Pyxis™ Pro Automated Medication Dispensing Solution, creating... Read more


Oscar Health Unveils New Choices and AI Tools Shaping the Future of Individual Healthcare for More Americans and Businesses

NEW YORK / Oct 20, 2025 / Business Wire / Oscar Health, Inc. (NYSE: OSCR), a leading healthcare technology company, is introducing a suite of easy-to-use health plans and AI features for millions of people for 2026 open enrollment. “Choice is power,” said Mark Bertolini, CEO of Oscar Health. “Oscar’s lineup of new products bring surprising new experiences and rewards to help members manage their health and get the most out of their plan. Everyone should be able to... Read more


Thermo Fisher Scientific to Accelerate Life Science Breakthroughs with OpenAI

WALTHAM, Mass. / Oct 16, 2025 / Business Wire / Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced plans to further increase the impact of Thermo Fisher’s proven growth strategy through the use of artificial intelligence (AI) with OpenAI. This collaboration will help to improve the speed and success of drug development, enabling customers to get medicines to patients faster and more cost effectively. Working with OpenAI, Thermo Fisher... Read more


SOPHiA GENETICS Launches AI-Powered Digital Twins to Enhance Intelligent Decision-Making in Oncology

BOSTON and ROLLE, Switzerland, Oct. 16, 2025 /CNW/ -- SOPHiA GENETICS (Nasdaq: SOPH), a leader in AI-driven precision medicine, today announced the launch of SOPHiA DDM™ Digital Twins, a breakthrough research technology that creates dynamic, virtual representations of individual patients to simulate potential outcomes and help oncologists make better treatment decisions.   SOPHiA DDM™ Digital Twins uses each patient's unique clinical, biological, imaging,... Read more


Veeva AI Agents to Be Released Across All Veeva Applications

Deep, industry-specific agents planned for availability starting this December PLEASANTON, Calif., Oct. 14, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced Veeva AI Agents are planned for availability starting December 2025 for commercial and across R&D and quality in 2026. Veeva AI adds agentic AI to the Veeva Vault Platform and deep, industry-specific agents for Veeva applications in all major areas, including clinical, regulatory, safety, quality,... Read more


CalciMedica and Telperian Announce Collaboration to Integrate Innovative Artificial Intelligence Engine to Analysis of Clinical Trials of Auxora™

AI tools will allow CalciMedica to analyze Phase 2 datasets to refine the target patient populations and efficacy endpoints for upcoming pivotal trials LA JOLLA, Calif., Oct. 14, 2025 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses,... Read more


Shuttle Pharmaceuticals to Enter $3.24 Billion AI Pharmaceutical Market

GAITHERSBURG, Md., Oct. 09, 2025 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH) (“Shuttle Pharma” or the “Company”), a discovery and development stage specialty pharmaceutical company, today announced the execution of a non-binding letter of Intent with Molecule.ai. Molecule.ai, a pioneering artificial intelligence company founded by AI scientist and researcher Dr. ZT Zhang, PhD, today announced the execution of a letter of Intent to... Read more


Claritev and iO Health Forge Strategic Relationship to Bring AI-Powered Revenue Cycle Management Optimization to the MENA Region

MCLEAN, Va. & DUBAI, United Arab Emirates / Oct 08, 2025 / Business Wire / Claritev Corporation (“Claritev” or the “Company”) (NYSE: CTEV), a technology, data and insights company focused on making healthcare more affordable, transparent and fair for all, and iO Health-FZE, an innovator in AI-driven healthcare technology, today announced a strategic agreement aimed at delivering Optima AI across the Middle East and North Africa (MENA). Through this agreement,... Read more


Intuitive expands AI and advanced imaging integration in Ion Endoluminal System

FDA-cleared software release enhances navigation and broadens access to advanced imaging for lung biopsy procedures  SUNNYVALE, Calif., Oct. 08, 2025 (GLOBE NEWSWIRE) -- Intuitive (NASDAQ:ISRG), a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery, today announced that the U.S. Food & Drug Administration (FDA) has cleared software advancements for the Ion endoluminal system (Ion). Ion, Intuitive’s robotic-assisted... Read more


Hoth Therapeutics Expands Artificial Intelligence Initiative, Selects NVIDIA AI Enterprise Platform

Under the new entitlement agreement, Hoth Therapeutics secures annual NVIDIA AI Enterprise Essentials licenses to support its GPU-powered infrastructure, enabling advanced machine learning and neural network modeling capabilities for pharmaceutical research NEW YORK, Oct. 8, 2025 /PRNewswire/ -- Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing innovative therapies for dermatological, oncological disorders, today... Read more


Oragenics Announces Strategic Partnership with Receptor.AI to Accelerate Pipeline Development

Clinical-Stage Biotechnology Company Leverages Artificial Intelligence SARASOTA, Fla. / Oct 07, 2025 / Business Wire / Oragenics, a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced a strategic collaboration with Receptor.AI, an artificial intelligence-driven drug profiling company, to accelerate the potential development of an expanded pharmaceutical-candidate portfolio for... Read more


Hyperfine Launches PULSE Platform to Accelerate Adoption and Innovation of AI-Powered Portable MRI

New subscription-based platform empowers a community of Swoop® system users worldwide to access advanced tools in support of imaging research and clinical studies in portable MRI. GUILFORD, Conn. / Oct 06, 2025 / Business Wire / Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared AI-powered portable MRI system for the brain—the Swoop® system—today announced the launch of the Portable... Read more


Evaxion Biotech to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

New biomarker and immune data from the ongoing phase 2 trial with EVX-01 will be presented at the Society for Immunotherapy of Cancer (SITC) 2025 Annual Meeting 




 











  
  &